Abstract:The past two decades of intense research have revealed a key role of the sphingolipid molecule sphingosine 1-phosphate (S1P) in regulating multiple physiological and pathophysiological processes including cell proliferation and survival, cell migration, inflammatory mediator synthesis and tissue remodeling. S1P mainly acts through five high-affinity G protein-coupled S1P receptors, which are ubiquitously expressed and mediate a complex network of signaling in a cell type dependent manner. S1P receptors have become an attractive pharmacological target to interfere with S1P-mediated cellular responses, which contribute to various autoimmune and inflammatory diseases. Pioneering in this field was the synthesis of FTY720 (fingolimod, Gilenya®) from myriocin, one of the metabolites of the fungus Isaria sinclairii known from traditional Chinese medicine for its antibacterial and energy boosting effect. Fingolimod turned out as a very potent immunomodulatory agent that subsequently passed all clinical trials successfully and is now approved for the treatment of relapsing-remitting multiple sclerosis. Pharmacologically, fingolimod was characterized as a non-selective agonist of all of the S1P receptors (S1PR), with the exception of S1P2, and in addition, as a selective S1P1 functional antagonist by induction of irreversible S1P1 internalization and degradation. Since proper lymphocyte trafficking depends on the expression of S1P1 on lymphocytes, the degradation of S1P1 leads to trapping and accumulation of lymphocytes in secondary lymphoid tissue, and consequently to a depletion of lymphocytes from the blood. Novel S1PR modulators are now being developed with a more selective receptor activation profile and improved pharmacokinetic characteristics. In this review, we will summarize the state-of-the-art approaches that target directly or indirectly S1P signaling and may be useful as novel strategies to treat autoimmune and inflammatory diseases.

Scavenger Receptor A in Immunity and Autoimmune Diseases: Compelling Evidence for Targeted Therapy

Small Molecule Inhibits Activity of Scavenger Receptor A: Lead Identification and Preliminary Studies

Understanding Molecular Interactions Between Scavenger Receptor A and Its Natural Product Inhibitors Through Molecular Modeling Studies.

Scavenger Receptor-a is a Biomarker and Effector of Rheumatoid Arthritis: A Large-Scale Multicenter Study.

Sphingosine-1-phosphate: a Potential Therapeutic Target for Rheumatoid Arthritis

Research progress of SIRTs activator resveratrol and its derivatives in autoimmune diseases

Nanocarrier Based Targeting of Vascular Cell Adhesion Molecule-1 for Diagnosis and Treatment of Atherosclerosis: Current Status and Future Perspectives

Therapeutic potential of chimeric antigen receptor based therapies in autoimmune diseases

Scavenger Receptors: Novel Roles in the Pathogenesis of Liver Inflammation and Cancer

Crucial Roles of RSAD2/viperin in Immunomodulation, Mitochondrial Metabolism and Autoimmune Diseases

SR-A Neutralizing Antibody: Potential Drug Candidate for Ameliorating Osteoclastogenesis in Rheumatoid Arthritis

Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A

Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases

The abscopal effect: Implications for drug discovery in autoimmunity

Class A1 scavenger receptor antibody improves murine colitis by influencing macrophage and gut microbiota

Differential roles of Scavenger receptor class B type�I: A�protective molecule and a facilitator of atherosclerosis (Review)

Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders

Targeting B cells and plasma cells in autoimmune diseases: from established treatments to novel therapeutic approaches

Combination of scavenger receptor-A with anti-cyclic citrullinated peptide antibody for the diagnosis of rheumatoid arthritis

Targeting AhR as a Novel Therapeutic Modality against Inflammatory Diseases

SR-BI as a target of natural products and its significance in cancer